Personalized treatment may help some liver cancer patients

	Tweet

A more personalized treatment for people with a type of metastatic liver cancer --hepatocellular carcinoma—may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers. Hepatocellular carcinoma (HCC) is the number three cause of cancer deaths in the world.

Hanning You, M.D., Ph.D., postdoctoral fellow, and C. Bart Rountree, M.D., assistant professor of pediatrics and pharmacology, targeted c-Met, a known receptor for hepatocyte growth factor, the substance that appears to drive liver cancer metastasis. In a pre-clinical translational study, they show that c-Met is overexpressed in metastatic liver cancer cells and is associated with a poor prognosis.

“In addition to finding that c-Met is a significant biomarker for liver cancer, we conducted an analysis of six published manuscripts and 1,051 patients,” said You. “Through this analysis we demonstrated and confirmed that c-Met activation is strongly associated with poor prognosis and aggressive features in patients with liver cancer tumors.”

Currently, physicians treat hepatocellular carcinoma with a “one size fits all” approach, so targeting c-Met may be an effective therapy for some patients.

“The five-year-survival of HCC is only 2 percent when diagnosed after metastasis,” said Rountree. “Sorafenib, the most recently approved mediation for advanced HCC, benefits patients with an extra two months survival.”

By targeting c-Met, researchers suppressed tumor growth and proliferation in a mouse model. They believe that molecular profiling will allow better treatment for the 45 percent of HCC patients who have c-Met positive tumors.

The research team is now looking to apply their findings to HCC in humans. The lab has applied to the National Cancer Institute to join a phase I trial using a c-Met inhibitor for advanced HCC.

“We are also working to build a second trial where we will establish a molecular profile of HCC patients before we start treatment, and then only give the c-Met inhibitor to the patients with a c-Met positive tumor, in effect personalizing their therapy,” Rountree said.

###

Funding was provided by Children’s Miracle Network, National Institutes of Health, American Cancer Society and Clinical and Translational Science Institute.

###

Contact: Matt Solovey

717-531-8606
Penn State

RELATED STORIES:
The relationship between body mass index and age at hepatocellular carcinoma onset   Liver cancer incidence lower in patients with nonalcoholic fatty liver disease than hepatitis C   Wilmot Researchers Create New Way to Study Liver Cancer   Omega-3 fatty acids inhibit the growth of liver cancer cells   More Reliable Biomarkers Needed for Liver Cancer Detection   New Technique in Treating Patients With Liver Cancer Proves Effective   The ignored virus that causes liver cancer   Liver Tumors Associated with Metabolic Syndrome Differ from Other Tumors   Sex hormone explains men’s higher liver cancer risk   Hepatitis C ups liver cancer risk, study confirms   Eating mandarins reduces the risk of liver disease, hardened arteries and insulin resistance   Study shows skin rash in patients treated for liver cancer determines survival   New study confirms link between nonalcoholic steatohepatitis and liver cancer   Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation   Type of Anesthesia May Affect Recurrence Risk after Liver Cancer Procedure   Researchers Identify Gene Linked to Aggressive Progression of Liver Cancer   Researchers find gene to fight liver cancer   A diagnostic marker in hepatocellular carcinoma   Liver cancer patients less likely to die on wait list than candidates without carcinomas   Statins may cut liver cancer risk in diabetics   Research in fish provides new clues about deadly form of liver cancer   Combination Therapy Improves Survival Time For Patients With Advanced Liver Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]